News | News By Subject | News by Disease News By Date | Search News

Blood Disorders (misc) News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
The Franchise That Could Bring in Another $20 Billion for Celgene (CELG)     11/23/2016
Investors Elated as Relypsa (RLYP)'s Phase IV Study of Veltassa Successful     8/31/2016
Bay Area's Portola (PTLA) Plummets as FDA Rejects AndexXa NDA     8/19/2016
Bad News for AstraZeneca PLC (AZN) is Good News for Relypsa (RLYP)     5/31/2016
Bay Area's Relypsa (RLYP) Falls on Unimpressive Veltassa Script Data     5/17/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
Portola (PTLA) Craters as Long-Acting Blood Thinner Betrixaban Missed Primary Goal in Phase III Study     3/25/2016
Eagle Pharma (EGRX) Plunges as the FDA Rejects Blood Thinner Kangio     3/18/2016
AstraZeneca PLC (AZN), Novo Nordisk A/S (NVO) Investors Pin Hopes on Data from Two Closely-Watched Trials     3/2/2016
Why Investors are Waiting Anxiously for Alnylam (ALNY)'s Blood Disease Data     12/4/2015
bluebird bio (BLUE) Plans Annual Hiring of 100+ for the Next Few Years     11/6/2015
Onco-Immunology Companies like Juno (JUNO), Novartis AG (NVS), Kite Pharma (KITE) Struggle to Mass Produce Custom Cancer Therapies     11/2/2015
With High-Powered Backing, Bay Area Vitesse Biologics is 'Getting Up to Speed'     10/23/2015
FDA Green Lights Boehringer Ingelheim's Blood Thinner Reversal Agent Praxbind     10/19/2015
FDA Approves Expanded Use of Promacta for Novartis AG (NVS)     8/25/2015

News from Around the Web
Experimental Tools To Clean Infected Blood Raise Hope For Fighting Major Killer, Harvard Medical School Study     3/23/2016
Novel Device Measures Stiffness And Stickiness Of Red Blood Cells, Case Western Reserve University Study     3/2/2016
Electric Fields Remove Nanoparticles From Blood With Ease, University of California, San Diego (UCSD) Study     11/24/2015
What Is Artificial Blood And Why Is The UK Going To Trial It?     6/25/2015
Extreme Exercise Linked To Blood Poisoning, Monash University Study     6/18/2015
How A Fluke Led Acceleron Pharma To A Crippling Blood Disease     7/18/2014
New Therapy for Blood Cancers Using Drug Combo, Report in Clinical Cancer Research     6/3/2011
Acetaminophen Tied to Blood Cancers, Fred Hutchinson Cancer Research Center Study     5/10/2011
IVIg No Help in Neonatal Blood Disease, Leiden University Medical Center Study Finds     3/21/2011
Higher Levels of Blood Protein Linked to Lower Respiratory Risks, University College London Study     2/16/2011
Breast Implants Linked to Blood Cancer, FDA Says     1/27/2011
Study Finds No Blood Clot Risk with Hormone Patch, INSERM Reveals     1/3/2011
Drug Combination Shows Promise for Newly Diagnosed Blood Cancer Patients, University of Michigan Comprehensive Cancer Center Study Finds     12/10/2010
New Research Reveals Danger of Combining Warfarin with Herbal and Dietary Supplements, Intermountain Medical Center Heart Institute Study     11/16/2010
Heartburn Drugs, Plavix Seem Safe to Take Together, Veterans Affairs Boston Healthcare System Study     10/7/2010

Press Releases
Acetylon Announces Upcoming Scientific Presentations On The Use Of Selective HDAC Inhibitors In Treating Genetic Blood Disorders And Cancers     12/2/2016
Genentech (RHHBY) Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society of Hematology 2016 Annual Meeting     11/3/2016
La Jolla Pharma (LJPC) Receives Positive Opinion From European Orphan Committee For LJPC-401     10/24/2016
Akari Therapeutics Announces Receipt Of Orphan Drug Designation For Coversin From The FDA For Treatment Of Paroxysmal Nocturnal Hemoglobinuria     9/12/2016
New Study Finds Continuous, Noninvasive Hemoglobin Monitoring Using Masimo (MASI) SpHB May Reduce Intraoperative Red Blood Cell Transfusion     9/9/2016
Portola (PTLA) Announces Validation Of Marketing Authorization Application (MAA) By EMA For Indexxa (Andexanet Alfa), A Factor Xa Inhibitor Antidote     8/19/2016
Akari Therapeutics Receives Approval From The UK Medicines & Healthcare Products Regulatory Agency To Conduct Phase II Trial In Paroxysmal Nocturnal Hemoglobinuria     7/13/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Paroxysmal Nocturnal Hemoglobinuria     7/12/2016
Apellis Pharma Announces Positive Results From Phase 1 Clinical Trials Of APL-2, A C3 Complement Inhibitor     6/23/2016
MorphoSys AG Reports Publication Of Clinical Case Report Of A Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission Of Currently 26 Months Under MOR208 Treatment     6/17/2016
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009     6/13/2016
Incyte (INCY) Release: New Phase III Data Show Jakafi (Ruxolitinib) Is Superior To Best Available Therapy In Patients With Polycythemia Vera (PV)     6/10/2016
Acceleron Pharma And Celgene (CELG) Announce Updated Results From An Ongoing Phase II Study Of Luspatercept In Beta-Thalassemia Presented At The 21st Congress Of The European Hematology Association     6/10/2016
Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity Of Its Lead Drug Candidates At 21st Congress Of The European Hematology Association     6/10/2016
Alexion (ALXN) Release: Late-Breaking Data Presented At European Hematology Association: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase I/II Study Exhibit Rapid And Sustained Reductions In LDH     6/10/2016

//-->